HAYWARD, Calif., February 18, 2025--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies ...

In the third quarter 2024, Arcus recognized $41 million in license and development services revenue related to the advancement of programs and Taiho's exercise of its option for the license of ...

New data from ARC-20, a Phase 1/1b study of the HIF-2a inhibitor casdatifan in clear cell renal cell carcinoma (ccRCC), will be presented in a rapid oral session by Dr. Toni Choueiri, Dana-Farber ...

Arcus Biosciences (NYSE:RCUS) will release its quarterly earnings report on Tuesday, 2025-05-06. Here's a brief overview for investors ahead of the announcement. Analysts anticipate Arcus ...

Bill Grossman is leaving Arcus Biosciences to take up a position at Gilead, putting him in charge of the Big Pharma's collaboration with his former employers. Grossman is currently chief medical ...

With new data out on Arcus Biosciences’ experimental HIF-2a inhibitor, one group of analysts figures the company could give Merck’s Welireg a run for its money in kidney cancer.